Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

These approvals were based on robust data which showed Trelegy Ellipta improved lung function and symptom control in adult asthma patients.” Regulators have started reviews of GSK's depemokimab ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... It launched Trelegy Ellipta, the countrys first single inhaler triple therapy (SITT) for ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

In short, the GSK share price has disappointed shareholders for years. I know, as I have a tiny holding in this business, while my wife has a more meaningful stake. For decades, GSK was my family ...

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...

After hours: 7:53:31 p.m. EST ...